Sternbach began work at the Hoffman-LaRoche Laboratories into the benzodiazepine group of drugs in 1933. In 1955 the first benzodiazepine, chlordiazepoxide (Librium), was synthesized and found to have sedating, anxiolytic and anticonvulsant properties. This drug was used by anaesthetists as a premedication. Further research culminated in the synthesis of diazepam, which was described by Sternbach and Reeder in 1961 and released commercially two years later.
Injectable diazepam was presented as a yellowish solution in 2 ml ampoules containing 10 mg. The solution caused precipitation or cloudiness when injected into various intravenous solutions but this did not appear to affect efficacy. The drug was initially manufactured for treatment of psychiatric disorders and was once again used by anaesthetists as premedication. The first intravenous use was reported by Farb who gave 10 to 30 mg intravenously as premedication for psychiatric interviews!
The first report of the use of diazepam as an intravenous induction agent was by J. Stovner and R. Endresen from the Norwegian Radium Hospital in Oslo. They wrote to the Lancet in 1965, "The rapid muscle-relaxation after intravenous diazepam ('Valium', Roche) in tetanus prompted us to try it in anaesthesia, although we knew that it acts on the central nervous system and not on the neuromuscular junction".
They went on to describe 50 cases where diazepam was used as an induction agent after premedication with morphine and hyoscine. The diazepam was diluted to 0.2% to avoid pain on induction, and 0.2 to 0.5 mg/kg was administered. The average time of induction was one minute. They found that it provided insufficient relaxation for laparotomies or intubation and therefore muscle relaxants were still required. They concluded that diazepam deserved extensive investigation as an induction agent as, in their hands, it produced less respiratory and circulatory depression than the barbiturates.
This letter prompted a reply from R. Cushman in Rhodesia, who reported that he had also used the drug with some success. However, he felt that its main application was in shocked patients where he found there was little disturbance in blood pressure or respiration when using 0.1 to 0.2 mg/kg.
In 1966, Andre McClish published an extensive study into diazepam. He studied 88 patients having various cardiac procedures, including many on bypass. The patients were given 5 to 20 mg of diazepam the night before, with 100 mg of oral barbiturate. Preoperatively they were given an average of 17.5 mg of intramuscular diazepam and 70 mg meperidine. Anaesthesia was then induced with a single intravenous dose of an average of 10.7 mg diazepam. McClish reported that "the patient experiences a feel-ing of well-being and relaxation as he gradually fades away into sleep".
Another study by A. Baker in Brisbane described an induction with diazepam (0.5 to 1.0 mg/kg) followed by suxamethonium after 45 seconds. "This time interval was not always enough to allow the patient to fall asleep, but in all cases the patient exhibited lateral nystagmus; this was taken to be indicative of an amnesic state. If the patient was awake there might be some alarm with the onset of fasciculations, but this disappeared with reassurance. In no instance did the patient remember this period."
The use of intravenous diazepam soon extended beyond operating theatres into dental surgeries and endoscopy suites. Dundee reported, "The dentist requires a technique which can be used single handedly in out-patients. It should reduce the nervous tension and blunt consciousness and memory of events without suppressing the voluntary efforts and reflexes of the patient … and should be relatively shortacting so that the patient may be able to leave soon after the treatment." Once again, large doses were employed, 10 to 20 mg, often repeated after 15 minutes for dental procedures.
In 1968, Rollason reported a case of cardiovascular collapse after diazepam. The patient, a fit young man, became hypotensive and bradycardic with cyanosis and vomiting. He responded rapidly to treatment but it was the first report of any major complication.
The same year Dundee and Brown concluded that diazepam was not an ideal induction agent. "There is a delay of about one minute in the onset of the soporific effect, and a great individual variation in response to the drug.… There was a remarkable absence of cardiovascular or other side-effects, even from very large doses, and amnesia was also an outstanding feature. The eventual place of diazepam in anaesthesia will not be as a competitor with established induction agents."
Ro 21-3981, or midazolam, was developed specifically to overcome these problems with diazepam. It is structurally similar to the other benzodiazepines but is water soluble. Trials began in 1978 to determine the sleep dose of intravenous midazolam and compare it with diazepam. An initial trial conducted by J. G. Reves and associates in Alabama concluded, "Ro 21-3981 is a promising intravenous anaesthetic agent. It appears superior to the closely related benzodiazepine, diazepam, in that it is more potent, less irritating, and shorter acting. The drug merits further clinical trials."
In the 1990s a soy bean emulsion of diazepam, Diazemuls, was released to overcome the problems of venous irritation and pain on injection. By this time midazolam had superseded diazepam in the operating theatre and Diazemuls never achieved great popularity.
Today, midazolam is well established in anaesthesia as an intravenous sedative and adjunct to various induction agents. It is also used intramuscularly and orally. Intravenous diazepam and Diazemuls are still available and are marketed for the treatment of epilepsy and anxiety disorders. CHRISTINE BALL, ROD WESTHORPE Geoffrey Kaye Museum of Anaesthetic History
